Targeted interleukin-2 therapy for melanoma by immunocytokines

Dermatologic Therapy

Volumn 10, Issue , 1999, Pages 53-61

  Becker, Jürgen C ^b   Lode, Holger N ^b   Thor Straten, Per ^b   Reisfeld, Ralph A ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANIMAL CELL; ANTIBODY PRODUCING CELL; CELL HYBRIDIZATION; HELPER CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MELANOMA; MOUSE; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0033005262     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Ehrlich P. The Croonian lecture: on immunity. Proc R Soc London 1900: 66: 424-437.
2. Milsten C, Brownlee GG, Cartweight EM, Jarvis JM, Proudfoot NJ. Sequence analysis of immunoglobulin light chain messenger RNA. Nature 1974: 252(5482): 354-359.
3. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997: 15(10): 3266-3274.
4. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 1985: 82(15): 5155-5159.
5. Gruber R, Holz E, Riethmuller G. Monoclonal antibodies in cancer therapy. Springer Semin Immunopathol 1996: 18(2): 243-251.
6. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998: 16(5): 1788-1794.
7. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies, SD, Reisfeld RA, Reithammer D. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A(2): 261-267.
8. George AJ, Spooner RA, Epenetos AA. Applications of monoclonal antibodies in clinical oncology. Immunol Today 1994: 15(12): 559-561.
9. Ghetie MA, Ghetie V, Vitetta ES. Immunotoxins for the treatment of B-cell lymphomas. Mol Med 1997: 3(7): 420-427.
10. Goldenberg DM, Larson SM, Reisfeld RA, Schlom J. Targeting cancer with radiolabeled antibodies. Immunol Today 1995: 16(6): 261-264.
11. Zhu H, Baxter LT, Jain RK. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 1997: 38(5): 731-741.
12. Maas RA, Dullens HF, den-Otter WD. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993: 36(3): 141-148.
13. Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 1988: 9(2): 58-62.
14. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 1987: 138(11): 4033-4041.
15. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998: 83(4): 797-805.
16. Nanni P, Rossi I, De GC, Landuzzi L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP, Lollini PL. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 1998: 58(6): 1225-1230.
17. Reisfeld RA, Mueller BM, Handgretinger R, Yu AL, Gillies SD. Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. Prog Brain Res 1994: 101: 201-212.
18. Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 1991: 10(3): 347-356.
19. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A 1992: 89(4): 1428-1432.
20. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993: 362(6422): 755-758.
21. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994: 91(20): 9626-9630.
22. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A 1996: 93(7): 2702-2707.
23. Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM, Epstein AL. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997: 89(12): 4437-4447.
24. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994: 153(10): 4775-4787.
25. Haraguchi M, Yamashiro S, Yamamoto A, Furukawa K, Takamiya K, Lloyd KO, Shiku H. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc Natl Acad Sci U S A 1994: 91(22): 10455-10459.
26. Yamashiro S, Haraguchi M, Furukawa K, Takamiya K, Yamamoto A, Nagata Y, Lloyd KO, Shiku H. Substrate specificity of beta 1,4-N-acetylgalactosaminyltransferase in vitro and in cDNA-transfected cells. GM2/GD2 synthase efficiently generates asialo-GM2 in certain cells. J Biol Chem 1995: 270(11): 6149-6155.
27. Decker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996: 183(5): 2361-2366.
28. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A 1996: 93(15): 7826-7831.
29. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996: 98(12): 2801-2804.
30. Sprent J. Antigen-presenting cells. Professionals and amateurs. Curr Biol 1995: 5(10): 1095-1097.
31. + T cells in vivo by IL-15. Immunity 1998: 8(5): 591-599.
32. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998: 392(6673): 245-252.
33. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996: 24(8): 859-862.
34. Thor-Straten P, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC. Activation of pre-existing T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci U S A 1998: 95(15): 8785-8790.
35. Thor-Straten P, Barfoed A, Seremet T, Saeterdal I, Zeuthen J, Guldberg P. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques 1998: 25(2): 244-250.
36. Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997: 20(1): 15-25.
37. Bloom MB, Perry LD, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997: 185(3): 453-459.
38. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995: 181(2): 799-804.
39. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 1995: 61(2): 253-260.
40. Becker JC, Terheyden P, Brocker EB. Molecular basis of T-cell dysfunction in melanoma. Melanoma Res 1997: 7(suppl 2): S51-S57.
41. Nestele FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998: 4(3): 328-332.
42. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998: 4(3): 321-327.